By Dr. Dimitrios Zarkadas, Ph.D. Director, Merck & Co Control of physical attributes of amorphous Active Pharmaceutical Ingredients (APIs) can be challenging due to processability issues, their wide variation...
Dr. Dimitrios Zarkadas has 20 years of experience in API development, commercialization and lifecycle management. He is currently leading API lifecycle management and development activities for the Merck Animal...
By Dr. Lotfi Derdour, Ph.D. Associate director, GlaxoSmithKline In recent years, there has been a increase in challenges related to low solubility1 and propensity for oiling-out2 in active pharmaceutical...
Lotfi completed his Bachelor’s degree in Chemical Engineering as top student in 1993 from University of Science and Technology, Oran, Algeria. He then obtained his master’s in Industrial Chemistry...
By Dr. Jeremy M. Merritt, Ph.D. Senior director and Group leader, Eli Lilly & Co. Automation plays a vital role in reducing development time in the pharmaceutical industry, both...
Jeremy M. Merritt (merrittje@lilly.com) is currently a Senior director and group leader at Eli Lilly and Co. in the synthetic molecule design and development organization (SMDD). He joined Lilly...
